| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
|
Lancet Oncol
|
2007
|
3.38
|
|
2
|
Imatinib mesylate in chordoma.
|
Cancer
|
2004
|
1.94
|
|
3
|
Phase II study of imatinib in advanced chordoma.
|
J Clin Oncol
|
2012
|
1.89
|
|
4
|
PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors.
|
Am J Surg Pathol
|
2008
|
1.65
|
|
5
|
Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.
|
Eur J Gastroenterol Hepatol
|
2007
|
1.56
|
|
6
|
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
|
Mol Cancer Ther
|
2009
|
1.52
|
|
7
|
KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2012
|
1.49
|
|
8
|
Response to sunitinib malate in advanced alveolar soft part sarcoma.
|
Clin Cancer Res
|
2009
|
1.39
|
|
9
|
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
|
Clin Cancer Res
|
2007
|
1.21
|
|
10
|
Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).
|
Oral Oncol
|
2009
|
1.19
|
|
11
|
9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
|
Cancer
|
2005
|
1.07
|
|
12
|
Targeted therapy in GIST: in silico modeling for prediction of resistance.
|
Nat Rev Clin Oncol
|
2011
|
1.05
|
|
13
|
KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
|
Cancer Res
|
2005
|
1.03
|
|
14
|
Carney triad: case report and molecular analysis of gastric tumor.
|
Hum Pathol
|
2005
|
1.01
|
|
15
|
c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2007
|
1.01
|
|
16
|
Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
|
Int J Cancer
|
2008
|
0.99
|
|
17
|
Molecular characterization of synovial sarcoma in children and adolescents: evidence of akt activation.
|
Transl Oncol
|
2008
|
0.98
|
|
18
|
Functional mapping of receptor tyrosine kinases in myxoid liposarcoma.
|
Clin Cancer Res
|
2010
|
0.95
|
|
19
|
Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.
|
Semin Oncol
|
2009
|
0.95
|
|
20
|
Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
|
Clin Cancer Res
|
2010
|
0.93
|
|
21
|
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
|
Mol Cancer Ther
|
2005
|
0.91
|
|
22
|
Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
|
J Natl Cancer Inst
|
2006
|
0.88
|
|
23
|
Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone.
|
Am J Surg Pathol
|
2003
|
0.86
|
|
24
|
A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.
|
J Gastroenterol
|
2011
|
0.83
|
|
25
|
Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
|
Cancer
|
2007
|
0.83
|
|
26
|
High CD133 expression levels in gastrointestinal stromal tumors.
|
Cytometry B Clin Cytom
|
2011
|
0.83
|
|
27
|
Activate and resist: L576P-KIT in GIST.
|
Mol Cancer Ther
|
2009
|
0.82
|
|
28
|
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?
|
Transl Oncol
|
2008
|
0.82
|
|
29
|
TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.
|
Transl Oncol
|
2008
|
0.81
|
|
30
|
Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.
|
Mol Oncol
|
2013
|
0.81
|
|
31
|
Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.
|
Histopathology
|
2014
|
0.81
|
|
32
|
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
|
J Thorac Oncol
|
2009
|
0.81
|
|
33
|
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
|
Med Oncol
|
2015
|
0.81
|
|
34
|
Targeted therapies: the rare cancer paradigm.
|
Mol Oncol
|
2009
|
0.79
|
|
35
|
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
|
J Thorac Oncol
|
2015
|
0.79
|
|
36
|
In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
|
Lab Invest
|
2013
|
0.79
|
|
37
|
Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y).
|
Mol Cancer Ther
|
2006
|
0.79
|
|
38
|
Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.
|
Neuro Oncol
|
2014
|
0.78
|
|
39
|
Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets.
|
Oncoimmunology
|
2013
|
0.78
|
|
40
|
A sporadic multiple GIST with unusual pathologic, molecular, and genetic features.
|
Am J Surg Pathol
|
2008
|
0.77
|
|
41
|
Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.
|
Int J Cancer
|
2011
|
0.77
|
|
42
|
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
|
J Natl Cancer Inst
|
2009
|
0.76
|
|
43
|
KIT activation in soft tissue sarcomas.
|
Am J Clin Pathol
|
2002
|
0.75
|
|
44
|
Platelet-derived growth factor receptor alpha expression improves the diagnostic assessment of gastrointestinal stromal tumours.
|
Histopathology
|
2012
|
0.75
|
|
45
|
Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
|
J Natl Cancer Inst
|
2003
|
0.75
|
|
46
|
Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.
|
J Transl Med
|
2011
|
0.75
|
|
47
|
The CD133 expression levels and its role as potential cancer stem cells marker in gastrointestinal stromal tumor.
|
Int J Cancer
|
2012
|
0.75
|
|
48
|
Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells.
|
J Thorac Oncol
|
2015
|
0.75
|
|
49
|
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
|
Int J Surg Pathol
|
2013
|
0.75
|
|
50
|
Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.
|
Anal Quant Cytol Histol
|
2010
|
0.75
|